What question did this study set out to answer?

This research aims to develop a Viremia-Integrated Risk Assessment (VIRA score) to predict 30-day mortality in COVID-19 pneumonia patients.

July 27, 2026PneumoniaOpen Access

Development and internal validation of a Viremia-Integrated Risk Assessment (VIRA score) for predicting mortality at diagnosis of COVID-19 pneumonia

View Full Paper

Ask AI

Bookmark

This research aims to develop a Viremia-Integrated Risk Assessment (VIRA score) to predict 30-day mortality in COVID-19 pneumonia patients.
Included 539 immunocompetent and 280 immunocompromised patients across two multicenter cohorts.
Employed multivariable logistic regression and assessed model performance with area under the curve (AUROC).
Integrated RNAemia, dyspnea, and male sex into the CURB-65 scoring system for improved predictions.
Mortality rate was 5.2% in immunocompetent and 15.0% in immunocompromised patients.
Incorporating RNAemia improved AUROC from 0.771 to 0.806 in immunocompetent and from 0.637 to 0.745 in immunocompromised patients.
VIRA score increased sensitivity to 72.7% in immunocompetent and 60.0% in immunocompromised patients at the high-risk cut-off.

No takes yet. Share an insight, caveat, or question.

Randomized trial develops VIRA score predicting mortality in COVID-19 pneumonia, indicating improved risk stratification for patients.

Salto-Alejandre et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark